Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-38678
Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
cancers-15-00297-v2.pdf1,22 MBAdobe PDFÖffnen/Anzeigen
Titel: PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer : A Retrospective Study
VerfasserIn: Banda, Amina
Privé, Bastiaan M.
Allach, Youssra
Uijen, Maike J. M.
Peters, Steffie M. B.
Loeff, Cato C.
Gotthardt, Martin
Muselaers, Constantijn H. J.
Witjes, J. Alfred
van Oort, Inge M.
Sedelaar, J. P. Michiel
Westdorp, Harm
Mehra, Niven
Khreish, Fadi
Ezziddin, Samer
Sabet, Amir
Kreissl, Michael C.
Winkens, Thomas
Seifert, Philipp
Janssen, Marcel J. R.
van Gemert, Willemijn A. M.
Nagarajah, James
Sprache: Englisch
In:
Titel: Cancers
Bandnummer: 15 (2023)
Heft: 1
Verlag/Plattform: MDPI
Erscheinungsjahr: 2022
Freie Schlagwörter: Actinium-225
Lutetium-177
early stage
prostate cancer
PSMA radioligand therapy
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [177Lu]Lu-PSMA- (177Lu-PSMA) or [225Ac]Ac-PSMA-radioligand treatment (225Ac-PSMA). In this retrospective study, we analyzed the safety and efficacy of PSMARLT in early-stage and hormone-sensitive metastatic prostate cancer patients. Methods: A retrospective study was performed in patients who received 177Lu-PSMA and/or 225Ac-PSMA with early-stage metastatic prostate cancer. The primary outcome parameter evaluated in this study was the progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcome parameters were prostate-specific antigen (PSA) response and the date of onset of CRPC state. Results: In total, 20 patients were included of which 18 patients received 177Lu-PSMA radioligand and two patients received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands. Patients received a median of 2 treatment cycles (range 1–6) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range (IQR) 5.2–7.4 GBq). PSMA-RLT was overall well-tolerated. The most common grade 1–2 side effects were xerostomia (n = 6) and fatigue (n = 8), which were only temporarily reported. One patient that received 225Ac-PSMA developed grade 3–4 bone marrow toxicity. The median PFS was 12 months (95% confidence interval (CI), 4.09–19.9 months). Seventeen (85%) patients had a ≥50% PSA response following PSMA-RLT. One patient developed CRPC 9 months following PSMA-RLT. Conclusions: In this small cohort study, PSMA-RLT appeared safe and showed encouraging efficacy for (metastasized) early-stage and hormone-sensitive prostate cancer patients. Prospective studies are awaited and should include long-term follow-up.
DOI der Erstveröffentlichung: 10.3390/cancers15010297
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-386782
hdl:20.500.11880/34879
http://dx.doi.org/10.22028/D291-38678
ISSN: 2072-6694
Datum des Eintrags: 16-Jan-2023
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Materials
In Beziehung stehendes Objekt: https://www.mdpi.com/article/10.3390/cancers15010297/s1
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Radiologie
Professur: M - Prof. Dr. Samer Ezziddin
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons